Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, AML, Biological, therapy sequence, Diseases, Non-Biological, Combinations, Therapies, checkpoint inhibitors, chemotherapy, Pediatric, enzyme inhibitors, white blood cells, Technology and Procedures, Cell Lineage, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , flow cytometry
Type: Oral
Hematology Disease Topics & Pathways:
Adult, AML, Biological, therapy sequence, Diseases, Non-Biological, Combinations, Therapies, checkpoint inhibitors, chemotherapy, Pediatric, enzyme inhibitors, white blood cells, Technology and Procedures, Cell Lineage, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , flow cytometry
Monday, December 7, 2020: 9:00 AM-10:30 AM
Moderators:
Laura C. Michaelis, MD, The Medical College of Wisconsin Inc.
and
Jeffrey E. Lancet, MD, H. Lee Moffitt Cancer Ctr. & Rsrch. Institute
Disclosures:
Lancet: Abbvie: Consultancy; Agios Pharmaceuticals: Consultancy, Honoraria; Astellas Pharma: Consultancy; Celgene: Consultancy, Research Funding; Daiichi Sankyo: Consultancy; ElevateBio Management: Consultancy; Jazz Pharmaceuticals: Consultancy; Pfizer: Consultancy.
9:00 AM
9:15 AM
9:30 AM
9:45 AM
10:15 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH